For years, I have been struck by a paradox that walks into Indian clinics every day: people of normal or only mildly elevated body weight by the numbers we have inherited from Western medicine, who nonetheless live with type 2 diabetes, fatty liver, dyslipidemia, and the cardiovascular risk profile of someone visibly obese. As a nutrition scientist working at the interface of clinical research and microbiome science, I kept arriving at the same question: if the simple equation of calories in versus calories out cannot fully explain why Indians become metabolically ill at “healthy” weights, what is the missing layer? Increasingly, the evidence pointed toward the trillions of microbes living quietly in our intestines, shaping how our bodies handle food, fat, and inflammation.
The pattern itself, first articulated by Indian clinicians and now well-documented across South Asian cohorts, is called the thin–fat phenotype. At any given body mass index, an Indian adult tends to carry more visceral fat the deep abdominal fat that wraps around organs and less skeletal muscle than a European counterpart. We are also more prone to ectopic fat in the liver and pancreas, and our insulin sensitivity falters earlier. Waist circumference and body-fat percentage often track metabolic risk far more accurately than BMI in our population. The roots of this phenotype run deep: low birth weight, postnatal catch-up growth, an evolutionary “thrifty” metabolism shaped by generations of scarcity, and a rapid nutritional transition toward refined carbohydrates and away from fermentable fibres. It is a phenotype that the standard global obesity yardstick was simply never designed to measure.
“The Western model of obesity, built around a number on a scale, fundamentally underestimates how Indian bodies become metabolically ill.”
The gut microbiome turns out to be far more than a digestive aide. The bacteria in our colon ferment dietary fibres into short-chain fatty acids particularly butyrate and propionate. These small molecules are not just energy substrates; they bind to receptors on the cells lining our gut and trigger the release of GLP-1 and PYY, the same satiety-and-glucose-control hormones that the new generation of weight-loss drugs target. Butyrate also strengthens the gut barrier itself. When that barrier weakens, fragments of bacterial cell walls leak into circulation and activate a low-grade, body-wide inflammation in fat, liver, and muscle that quietly impairs insulin signalling and accelerates the deposition of visceral fat. Microbial products also reshape bile-acid chemistry and how our adipose tissue stores triglycerides. The gut, in short, is a metabolic organ and dysbiosis lands us squarely in the territory of insulin resistance and cardiovascular risk.
What makes this picture particularly relevant for India is a nutritional irony. Our traditional diets are cereal- and legume-based, with the structural conditions for excellent microbial fermentation. But high-quality fermentable fibres resistant starches, soluble fibres, whole-grain matrices have been steadily refined out of the modern Indian plate in favour of polished rice, white flour, and ultra-processed snacks. The microbes that produce butyrate need substrate, and we have largely stopped feeding them. Layered on top is an Indian-specific microbiome signature: lower alpha-diversity in cross-population comparisons, Prevotella-dominant configurations whose fermentative output depends heavily on dietary diversity, and reduced abundance of key butyrate producers such as Faecalibacterium in adults with obesity. The same gut environment that should be a metabolic asset has been weakened just as the metabolic stress of urban life has risen.
The finding that surprised me most as we synthesised this literature was the bidirectional relationship between GLP-1 receptor agonists and the gut microbiome. We tend to talk about these drugs—semaglutide, tirzepatide, and the newer dual agonists—as direct hormonal interventions. But emerging evidence shows that they also reshape the gut ecosystem through delayed gastric emptying, altered bile-acid flow, and changes in nutrient transit, while the microbiome in turn modulates how patients respond to the drugs and how well they tolerate them. It reframes synbiotics and fibre-rich nutrition not as alternatives to pharmacotherapy but as ecological partners. Durable metabolic health may emerge from the conversation between drug, microbe, and diet rather than from any one of them in isolation—a perspective that quietly upends the old framing of “diet versus drugs.”
“The gut microbiome is not a competing therapy to incretin drugs. It is the ecological substrate on which those drugs work.”
For the general reader, the practical implication is gentler than the headlines often suggest. There is no single magic strain or supplement that will undo metabolic disease. But the direction of the evidence converges on actions genuinely available to most Indian households: eat for the microbes by reintroducing fermentable fibres whole pulses, millets, vegetables, fruit, and traditionally fermented foods such as dahi, kanji, and idli batter alongside whatever else one eats. Where diet alone falls short, well-characterised synbiotics probiotic strains paired with matched prebiotic substrates are emerging as a scalable adjunct. In a recent ninety-day randomised, placebo-controlled trial in adults with overweight, a multi-strain synbiotic produced measurable reductions in body weight, waist circumference, and insulin-resistance markers. None of this replaces lifestyle, sleep, or movement; it complements them. And it shifts the cultural framing of obesity treatment in India from one of failure and willpower to one of biology, ecology, and feeding the right system.
Several questions remain genuinely open. We do not yet have phenotype-specific long-term trials in South Asians: most data come from short studies in mixed populations, and the durability of synbiotic effects on weight, glycaemic control, and cardiovascular outcomes is unproven over years. Strain specificity matters not all probiotics are equivalent, and matching strains to individuals based on baseline microbiome composition is still aspirational rather than clinical. The virome and mycobiome the viral and fungal members of the gut community are barely mapped in Indian populations. Larger questions sit on top: how do we standardise commercial formulations and verify viability? How do synbiotics interact with GLP-1 agonists in routine practice? Will we eventually see precision microbiome therapy guided by multi-omics rather than population averages? My own work in the years ahead will sit at this intersection, drawing on the insights of clinicians, microbiologists, and policy researchers including my co-authors Drs. Nirmal Kumar Ganguly, Sanjay Kalra, Nitin Kapoor, and Manorama Bakshi to translate this science into something that meaningfully serves Indian metabolic health.
Reframing obesity through a gut–metabolic lens does not solve India’s metabolic crisis on its own. But it offers something the calorie-centric paradigm has not: a mechanism that fits the patient in front of us, a culturally compatible set of interventions, and a research direction in which India is uniquely positioned to lead. That, I think, is worth getting right.
